A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of UCB0022 in Study Participants With Advanced Parkinson's Disease (ATLANTIS)
A Multicenter Phase 2, Double-blind, Placebo-controlled, Randomized, Parallel-group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of UCB0022 in Study Participants With Advanced Parkinson's Disease
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: UCB Cares
- Phone Number: 1-844-599-2273 (USA)
- Email: ucbcares@ucb.com
Study Contact Backup
- Name: UCB Cares
- Phone Number: 001 844 599 2273
- Email: UCBCares@ucb.com
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85004
- Pd0060 50506
-
Scottsdale, Arizona, United States, 85258
- Pd0060 50590
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72205
- Pd0060 50608
-
-
California
-
Fountain Valley, California, United States, 92708
- Pd0060 50519
-
Fresno, California, United States, 93710
- Pd0060 50428
-
Loma Linda, California, United States, 92354
- Pd0060 50601
-
Los Alamitos, California, United States, 90720
- Pd0060 50589
-
Los Angeles, California, United States, 90033
- Pd0060 50587
-
Pasadena, California, United States, 91106
- Pd0060 50452
-
-
Colorado
-
Englewood, Colorado, United States, 80113
- Pd0060 50598
-
-
Connecticut
-
New Haven, Connecticut, United States, 06519
- Pd0060 50628
-
-
Delaware
-
Newark, Delaware, United States, 19713
- Pd0060 50610
-
-
Florida
-
Altamonte Springs, Florida, United States, 32714
- Pd0060 50600
-
Aventura, Florida, United States, 33180
- Pd0060 50616
-
Boca Raton, Florida, United States, 33486
- Pd0060 50596
-
Bradenton, Florida, United States, 34205
- Pd0060 50524
-
DeLand, Florida, United States, 32720
- Pd0060 50647
-
Doral, Florida, United States, 33172
- Pd0060 50577
-
Hollywood, Florida, United States, 33021
- Pd0060 50584
-
Miami, Florida, United States, 33122
- Pd0060 50582
-
Miami, Florida, United States, 33125
- Pd0060 50579
-
Miami, Florida, United States, 33133
- Pd0060 50449
-
Miami, Florida, United States, 33176
- Pd0060 50580
-
Naples, Florida, United States, 34105
- Pd0060 50597
-
Ocala, Florida, United States, 34470
- Pd0060 50591
-
Port Orange, Florida, United States, 32127
- Pd0060 50605
-
St. Petersburg, Florida, United States, 33710
- Pd0060 50620
-
Tampa, Florida, United States, 33609
- Pd0060 50603
-
Winter Park, Florida, United States, 32789
- Pd0060 50585
-
-
Georgia
-
Augusta, Georgia, United States, 30912
- Pd0060 50075
-
-
Indiana
-
Indianapolis, Indiana, United States, 46256
- Pd0060 50595
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- Pd0060 50319
-
-
Kansas
-
Kansas City, Kansas, United States, 66160
- Pd0060 50074
-
-
Kentucky
-
Lexington, Kentucky, United States, 40536-0284
- Pd0060 50561
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02118
- Pd0060 50615
-
Boston, Massachusetts, United States, 02215
- Pd0060 50085
-
North Dartmouth, Massachusetts, United States, 02747
- Pd0060 50627
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109-0944
- Pd0060 50110
-
East Lansing, Michigan, United States, 48824
- Pd0060 50545
-
Farmington Hills, Michigan, United States, 48334
- Pd0060 50386
-
Grand Rapids, Michigan, United States, 49503
- Pd0060 50613
-
-
New York
-
New York, New York, United States, 10021
- Pd0060 50614
-
New York, New York, United States, 10029
- Pd0060 50521
-
-
North Carolina
-
Raleigh, North Carolina, United States, 27607
- Pd0060 50612
-
-
Ohio
-
Centerville, Ohio, United States, 45459
- Pd0060 50087
-
Cleveland, Ohio, United States, 44195
- Pd0060 50622
-
Columbus, Ohio, United States, 43221
- Pd0060 50076
-
Dayton, Ohio, United States, 45449
- Pd0060 50604
-
Toledo, Ohio, United States, 43614
- Pd0060 50527
-
-
Oklahoma
-
Tulsa, Oklahoma, United States, 74136
- Pd0060 50398
-
-
Oregon
-
Portland, Oregon, United States, 97210
- Pd0060 50607
-
-
South Carolina
-
Rock Hill, South Carolina, United States, 29732
- Pd0060 50619
-
-
Texas
-
Round Rock, Texas, United States, 78681
- Pd0060 50496
-
San Antonio, Texas, United States, 78229
- Pd0060 50568
-
-
Utah
-
Salt Lake City, Utah, United States, 84108
- Pd0060 50537
-
-
Virginia
-
Henrico, Virginia, United States, 23233
- Pd0060 50143
-
Virginia Beach, Virginia, United States, 23456
- Pd0060 50534
-
-
Washington
-
Bellevue, Washington, United States, 98004
- Pd0060 50440
-
Kirkland, Washington, United States, 98034
- Pd0060 50292
-
Spokane, Washington, United States, 99202
- Pd0060 50419
-
-
West Virginia
-
Crab Orchard, West Virginia, United States, 25827
- Pd0060 50402
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Study participant must be 35 to 85 years of age (inclusive) at the time of signing the informed consent form (ICF)
- Study participant is diagnosed with Parkinson's disease (PD) (based on the United Kingdom Parkinson's Disease Society Brain Bank Diagnostic criteria performed at the Screening Visit) and diagnosed ≥5 years before the Screening Visit (based on historical medical- information documented by the investigator)
- Study participant has significant daily motor fluctuations
- Study participant is able to complete a Hauser PD symptoms diary and differentiate between the ON and OFF states
- Study participant is responsive to levodopa and currently receiving treatment with oral daily doses of levodopa combination (levodopa/carbidopa or levodopa/benserazide) with or without oral adjunctive antiparkinsonian therapies (based on historical clinical data)
- Study participant has disease severity Stages I-III (modified Hoehn and Yahr staging) during ON state
- Study participant agrees to not post personal medical data or information related to the study on social media until study completion
- Study participant has body weight ≥45 kg and body mass index within 18 to 30 kg/m^2 (inclusive)
Study participant may be male or female:
- A male study participant must agree to use contraception during the Treatment Period and for at least 2 weeks after the last dose of study treatment and refrain from donating sperm during this period
- A female study participant must not be a woman of childbearing potential (WOCBP)
Exclusion Criteria:
- Study participant is diagnosed with any form of Parkinsonism other than idiopathic PD (eg, atypical or secondary Parkinsonism)
- Study participant is diagnosed with dementia or has important cognitive dysfunction, as determined by Montreal Cognitive Assessment (MoCA) <23 at screening
- Study participant has a history of neurosurgical intervention for PD (including DBS, thalamotomy, and experimental cell therapy or gene therapy)
- Participant has a severe peak dose or biphasic dyskinesia at screening, defined by Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) items 4.2 score 4 or as per investigator opinion
- Participant has a history of major depression or psychotic disorder or any other psychiatric condition within the past 5 years, that, as per investigator opinion, could jeopardize or would compromise the study participant's ability to participate in the study
- Study participant has a history of narrow angle glaucoma
- Study participant has a history of melanoma
- Study participant has current untreated hypertension
- Study participant has a history of hypertensive crisis and/or hypertensive encephalopathy, unless the underlying cause was unequivocally identified and has been removed
- Study participant has orthostatic hypotension requiring medication or a current history of "clinically significant" orthostatic hypotension as per the investigator's opinion (eg, recurrent orthostatic presyncope or syncope)
- Study participant has a history over the past 12 months or between the Screening and Baseline Visits of any clinically significant arrythmia, myocardial infarction, stroke, transient ischemic attack, moderate or severe congestive heart failure (either New York Heart Association Class III or IV or known ejection fraction <40%)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: UCB0022-Dose A
Study participants randomized to this arm will receive UCB0022 Dose A orally administered as tablet during the Treatment Period.
|
Study participants will receive UCB0022 dose A or B orally administered as tablet at pre-specified time points during the Treatment Period.
|
|
Experimental: UCB0022-Dose B
Study participants randomized to this arm will receive UCB0022 Dose B orally administered as tablet during the Treatment Period.
|
Study participants will receive UCB0022 dose A or B orally administered as tablet at pre-specified time points during the Treatment Period.
|
|
Placebo Comparator: Placebo
Study participants randomized to this arm will receive matching placebo orally administered as tablet during the Treatment Period.
|
Study participants will receive placebo orally administered as tablet at pre-specified time points during the study.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from Baseline to Visit 9 (Day 70) in the average number of hours/day of OFF time, as assessed by the study participant-completed Hauser PD symptoms diary over 3 consecutive days
Time Frame: From Baseline (Day 1) to Visit 9 (Day 70)
|
The Hauser Parkinson's disease (PD) symptoms diary is a study participant-completed diary that records the daily ON time and OFF time of study participants with PD with motor fluctuations and dyskinesia.
|
From Baseline (Day 1) to Visit 9 (Day 70)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of treatment-emergent adverse events (TEAEs)
Time Frame: From Baseline (Day 1) to End of Safety Follow-up (up to Week 12)
|
An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP.
An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP.
TEAEs are defined as AEs starting after the time of first IMP administration up to and including 2 weeks after the final dose.
|
From Baseline (Day 1) to End of Safety Follow-up (up to Week 12)
|
|
Incidence of treatment-emergent serious adverse events (SAEs)
Time Frame: From Baseline (Day 1) to End of Safety Follow-up (up to Week 12)
|
A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose:
|
From Baseline (Day 1) to End of Safety Follow-up (up to Week 12)
|
|
Incidence of TEAEs leading to withdrawal from the study
Time Frame: From Baseline (Day 1) to End of Safety Follow-up (up to Week 12)
|
An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of IMP, whether or not considered related to the IMP.
An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP.
TEAEs are defined as AEs starting after the time of first IMP administration up to and including 2 weeks after the final dose.
|
From Baseline (Day 1) to End of Safety Follow-up (up to Week 12)
|
|
Average Ctrough of UCB0022 and its active N-desmethyl-UCB0022 metabolite at Visit 9 (Day 70)
Time Frame: at Visit 9 (Day 70)
|
Ctrough: The predose observed plasma concentration (average, per visit) will be plotted and depicted graphically to assess trajectory to steady-state for parent and active metabolites.
|
at Visit 9 (Day 70)
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: UCB Cares, 001 844 599 2273
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- PD0060
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.